

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

ProteoGenex

RRID:SCR_013844

Type: Tool

Proper Citation

ProteoGenex (RRID:SCR_013844)

Resource Information

URL: <http://www.proteogenex.com>

Proper Citation: ProteoGenex (RRID:SCR_013844)

Description: Commercial biomaterial supply resource which provides an extensive biorepository as well as an exclusive human tissue-based research service. The biobank contains defined and categorized clinical samples of tissues, blood, serum, bone marrow, and tissue microarrays. ProteoGenex collects biomaterials for a variety of fields, including oncology, neurology, and immunology. Normal tissues are collected, as well. All samples are supported by pathology information and patient clinical history documentation. ProteoGenex also offers custom collection design.

Synonyms: ProteoGenex Corporation

Resource Type: biomaterial supply resource, commercial organization, material resource

Keywords: biomaterial supply resource, biorepository, biobank, tissue, human tissue, custom collection

Resource Name: ProteoGenex

Resource ID: SCR_013844

Record Creation Time: 20220129T080318+0000

Record Last Update: 20260905T132741+0000

Ratings and Alerts

No rating or validation information has been found for ProteoGenex.

No alerts have been found for ProteoGenex.

Data and Source Information

Usage and Citation Metrics

We found 147 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Owari K, et al. (2026) Selective removal of soluble FLT-1 using a high-affinity DNA aptamer for potential apheresis treatment of preeclampsia. *Scientific reports*, 16(1).

Pillarisetti K, et al. (2026) Ramantamig (JNJ-79635322), a novel T-cell-engaging trispecific antibody targeting BCMA, GPRC5D, and CD3, in multiple myeloma models. *Blood*, 147(8), 834.

Kimura N, et al. (2026) CLDN6 Expression Plasticity in Ovarian Cancer: Insights into Therapeutic Optimization for CLDN6-Targeted Immunotherapy. *Cancer research communications*, 6(2), 383.

He EY, et al. (2026) A Prospective, Cross-Sectional, Multicenter Study Evaluating a Multi-Target Blood Protein in Vitro Diagnostic Test for Colorectal Cancer. *Journal of gastrointestinal cancer*, 57(1), 19.

Tsapanou-Katranara T, et al. (2025) Neutrophil-mediated degradation of type III collagen is elevated in inflammatory bowel disease and DSS-induced colitis reflecting early mucosal damage. *Scientific reports*, 15(1), 21132.

Iwamoto Y, et al. (2025) High throughput analysis of rare nanoparticles with deep-enhanced sensitivity via unsupervised denoising. *Nature communications*, 16(1), 1728.

Nishidate M, et al. (2025) Development and validation of highly sensitive ligand binding assay to measure soluble DLL3 concentration in human serum. *Bioanalysis*, 17(11), 725.

Nikseresht S, et al. (2025) Improved breast cancer diagnosis using a CA15-3 capture antibody-lectin sandwich assay. *Breast cancer research and treatment*, 211(3), 605.

Kumabe H, et al. (2025) Proteome profile differences among human, monkey, and mouse brain microvessels and cultured brain microvascular endothelial cells. *Fluids and barriers of the CNS*, 22(1), 53.

Zou J, et al. (2025) KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML. *Leukemia*, 39(8), 1848.

Kim H, et al. (2025) Noninvasive Assessment of β -Secretase Activity Through Click Chemistry-Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer's Disease. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 12(26), e2415289.

Komaki H, et al. (2025) Phase 1/2 trial of brogadirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy. *Cell reports. Medicine*, 6(1), 101901.

Georgakopoulos-Soares I, et al. (2025) Leveraging sequences missing from the human genome to diagnose cancer. *Communications medicine*, 5(1), 363.

Ogata S, et al. (2024) Isolation method of brain microvessels from small frozen human brain tissue for blood-brain barrier protein expression analysis. *Fluids and barriers of the CNS*, 21(1), 106.

Daigre J, et al. (2024) Preclinical Evaluation of Novel Folate Receptor 1-Directed CAR T Cells for Ovarian Cancer. *Cancers*, 16(2).

Tsushima H, et al. (2024) Roles of pigment epithelium-derived factor in exercise-induced suppression of senescence and its impact on lung pathology in mice. *Aging*, 16(13), 10670.

Alexdottir MS, et al. (2024) Neutrophil-mediated type IV collagen degradation is elevated in patients with mild endoscopic ulcerative colitis reflecting early mucosal destruction. *Scientific reports*, 14(1), 1641.

Danilov SM, et al. (2024) Carriers of Heterozygous Loss-of-Function ACE Mutations Are at Risk for Alzheimer's Disease. *Biomedicines*, 12(1).

Yasui T, et al. (2024) Early Cancer Detection via Multi-microRNA Profiling of Urinary Exosomes Captured by Nanowires. *Analytical chemistry*, 96(43), 17145.

Winn-Deen ES, et al. (2024) Improving Specificity for Ovarian Cancer Screening Using a Novel Extracellular Vesicle-Based Blood Test: Performance in a Training and Verification Cohort. *The Journal of molecular diagnostics : JMD*, 26(12), 1129.